Exosomes: Potential Targets for the Diagnosis and Treatment of Neuropsychiatric Disorders

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2024 Jan 30

PMID 38287384

Authors

Haorao Li

Yanling Yuan

Qinglian Xie

Zaiquan Dong

Affiliations

Soon will be listed here.

Abstract

The field of neuropsychiatry is considered a middle ground between neurological and psychiatric disorders, thereby bridging the conventional boundaries between matter and mind, consciousness, and function. Neuropsychiatry aims to evaluate and treat cognitive, behavioral, and emotional disorders in individuals with neurological conditions. However, the pathophysiology of these disorders is not yet fully understood, and objective biological indicators for these conditions are currently lacking. Treatment options are also limited due to the blood-brain barrier, which results in poor treatment effects. Additionally, many drugs, particularly antipsychotic drugs, have adverse reactions, which make them difficult to tolerate for patients. As a result, patients often abandon treatment owing to these adverse reactions. Since the discovery of exosomes in 1983, they have been extensively studied in various diseases owing to their potential as nanocellulators for information exchange between cells. Because exosomes can freely travel between the center and periphery, brain-derived exosomes can reflect the state of the brain, which has considerable advantages in diagnosis and treatment. In addition, administration of engineered exosomes can improve therapeutic efficacy, allow lesion targeting, ensure drug stability, and prevent systemic adverse effects. Therefore, this article reviews the source and biological function of exosomes, relationship between exosomes and the blood-brain barrier, relationship between exosomes and the pathological mechanism of neuropsychiatric disorders, exosomes in the diagnosis and treatment of neuropsychiatric disorders, and application of engineered exosomes in neuropsychiatric disorders.

Citing Articles

Circular RNAs: novel noncoding players in male infertility.

Babakhanzadeh E, Hoseininasab F, Khodadadian A, Nazari M, Hajati R, Ghafouri-Fard S Hereditas. 2024; 161(1):46.

PMID: 39551760 PMC: 11572108. DOI: 10.1186/s41065-024-00346-8.

Exosome nanovesicles: biomarkers and new strategies for treatment of human diseases.

Xu C, Jiang C, Li Z, Gao H, Xian J, Guo W MedComm (2020). 2024; 5(8):e660.

PMID: 39015555 PMC: 11247338. DOI: 10.1002/mco2.660.

Dual-Omics Approach Unveils Novel Perspective on the Quality Control of Genetically Engineered Exosomes.

Olson C, Ivanov K, Boyes D, Bengford D, Ku J, Flojo R Pharmaceutics. 2024; 16(6).

PMID: 38931944 PMC: 11207238. DOI: 10.3390/pharmaceutics16060824.

Multiomics analysis of platelet-rich plasma promoting biological performance of mesenchymal stem cells.

Dai P, Wu Y, Gao Y, Li M, Zhu M, Xu H BMC Genomics. 2024; 25(1):564.

PMID: 38840037 PMC: 11151483. DOI: 10.1186/s12864-024-10329-8.

References

Liu J, Clough S, Hutchinson A, Adamah-Biassi E, Popovska-Gorevski M, Dubocovich M . MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol. 2015; 56:361-83. PMC: 5091650. DOI: 10.1146/annurev-pharmtox-010814-124742. View

Jia L, Qiu Q, Zhang H, Chu L, Du Y, Zhang J . Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement. 2019; 15(8):1071-1080. DOI: 10.1016/j.jalz.2019.05.002. View

Kuwano N, Kato T, Mitsuhashi M, Sato-Kasai M, Shimokawa N, Hayakawa K . Neuron-related blood inflammatory markers as an objective evaluation tool for major depressive disorder: An exploratory pilot case-control study. J Affect Disord. 2018; 240:88-98. DOI: 10.1016/j.jad.2018.07.040. View

Goetzl E, Abner E, Jicha G, Kapogiannis D, Schwartz J . Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease. FASEB J. 2017; 32(2):888-893. PMC: 5888398. DOI: 10.1096/fj.201700731R. View

Hu Y, Zhao M, Wang H, Guo Y, Cheng X, Zhao T . Exosome-sheathed ROS-responsive nanogel to improve targeted therapy in perimenopausal depression. J Nanobiotechnology. 2023; 21(1):261. PMC: 10408189. DOI: 10.1186/s12951-023-02005-y. View

Huber C, Callegari E, Paez M, Romanova S, Wang H . Heat Shock-Induced Extracellular Vesicles Derived from Neural Stem Cells Confer Marked Neuroprotection Against Oxidative Stress and Amyloid-β-Caused Neurotoxicity. Mol Neurobiol. 2022; 59(12):7404-7412. PMC: 10088367. DOI: 10.1007/s12035-022-03055-3. View

Scarcelli T, Jordao J, OReilly M, Ellens N, Hynynen K, Aubert I . Stimulation of hippocampal neurogenesis by transcranial focused ultrasound and microbubbles in adult mice. Brain Stimul. 2014; 7(2):304-7. PMC: 4103630. DOI: 10.1016/j.brs.2013.12.012. View

Ozansoy M, Ozansoy M, Yulug B, Cankaya S, Kilic E, Goktekin S . Melatonin affects the release of exosomes and tau-content in in vitro amyloid-beta toxicity model. J Clin Neurosci. 2020; 73:237-244. DOI: 10.1016/j.jocn.2019.11.046. View

Fries G, Lima C, Valvassori S, Zunta-Soares G, Soares J, Quevedo J . Preliminary investigation of peripheral extracellular vesicles' microRNAs in bipolar disorder. J Affect Disord. 2019; 255:10-14. DOI: 10.1016/j.jad.2019.05.020. View

10.

Dugger B, Dickson D . Pathology of Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2017; 9(7). PMC: 5495060. DOI: 10.1101/cshperspect.a028035. View

11.

Yang C, Wu Y, Wang L, Li S, Zhou J, Tan Y . Glioma-derived exosomes hijack the blood-brain barrier to facilitate nanocapsule delivery via LCN2. J Control Release. 2022; 345:537-548. DOI: 10.1016/j.jconrel.2022.03.038. View

12.

Albers D, Beal M . Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm Suppl. 2000; 59:133-54. DOI: 10.1007/978-3-7091-6781-6_16. View

13.

Barile L, Vassalli G . Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017; 174:63-78. DOI: 10.1016/j.pharmthera.2017.02.020. View

14.

Tenchov R, Sasso J, Wang X, Liaw W, Chen C, Zhou Q . Exosomes─Nature's Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics. ACS Nano. 2022; 16(11):17802-17846. PMC: 9706680. DOI: 10.1021/acsnano.2c08774. View

15.

Ji C, Tang Y, Zhang Y, Li C, Liang H, Ding L . Microglial glutaminase 1 deficiency mitigates neuroinflammation associated depression. Brain Behav Immun. 2021; 99:231-245. DOI: 10.1016/j.bbi.2021.10.009. View

16.

Gao S, Bai L, Jia S, Meng C . Small Extracellular Vesicles of M1-BV2 Microglia Induce Neuronal PC12 Cells Apoptosis via the Competing Endogenous Mechanism of CircRNAs. Genes (Basel). 2022; 13(9). PMC: 9498615. DOI: 10.3390/genes13091603. View

17.

Honorato-Mauer J, Xavier G, Ota V, Chehimi S, Mafra F, Cuoco C . Alterations in microRNA of extracellular vesicles associated with major depression, attention-deficit/hyperactivity and anxiety disorders in adolescents. Transl Psychiatry. 2023; 13(1):47. PMC: 9902559. DOI: 10.1038/s41398-023-02326-4. View

18.

Qu M, Lin Q, Huang L, Fu Y, Wang L, He S . Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson's disease. J Control Release. 2018; 287:156-166. DOI: 10.1016/j.jconrel.2018.08.035. View

19.

Amoah S, Rodriguez B, Logothetis C, Chander P, Sellgren C, Weick J . Exosomal secretion of a psychosis-altered miRNA that regulates glutamate receptor expression is affected by antipsychotics. Neuropsychopharmacology. 2019; 45(4):656-665. PMC: 7021900. DOI: 10.1038/s41386-019-0579-1. View

20.

Rastogi S, Sharma V, Bharti P, Rani K, Modi G, Nikolajeff F . The Evolving Landscape of Exosomes in Neurodegenerative Diseases: Exosomes Characteristics and a Promising Role in Early Diagnosis. Int J Mol Sci. 2021; 22(1). PMC: 7795439. DOI: 10.3390/ijms22010440. View